Article
Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
Cancer medicine - 1 Jul 2021
Zhang Yujun, Xiong Liwen, Xie Fangfang, Zheng Xiaoxuan, Li Ying, Zhu Lei, Sun Jiayuan
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) has been considered as an effective treatment in epidermal growth factor receptor-mutant (EGFR-mutant) advanced non-small cell lung cancer (NSCLC). However, most patients develop acquired resistance eventually. Here, we compared and analyzed the genetic alterations between tissue assay and circulating tumor DNA (ctDNA) and further...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.